 Whilst not a primary comparison, the study will nevertheless still have 80 power to detect a 5.5 month difference between the two experimental arms as a secondary comparison based on a level of significance of 1.7. Secondary endpoints include treatment related toxicity. Toxicity analyses will include treatment-received population, which includes all patients who received at least 1 dose of study treatment. Toxicity will be described by tabulating the proportions of patients with a worst toxicity grade of 0, 1, 2, 3, or 4 for each of the relevant NCI CTC AE scales. 